Find and Pitch Jounalists, Get Your Story Covered

Tags: Acino M8 Pharmaceuticals acquisition Samsung cloud gaming

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more - 3 days ago STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more - 4 days ago STAT+: Pharmalittle: We’re reading about a Vaxcyte vaccine, Ozempic shortages, and more - 12 days ago STAT+: Pharmalittle: We’re reading about FDA rejecting MDMA; a nasal spray for allergic reactions, and more - about 1 month ago STAT+: Pharmalittle: We’re reading about Sanders dogging Novo Nordisk, Teva patents, and more - 3 months ago STAT+: Pharmalittle: We’re reading about an Amgen obesity drug, a Senate bill on shortages, and more - 5 months ago STAT+: Pharmalittle: We’re reading about a European probe into vaccine talks; net drug prices falling, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Amgen suing Colorado over drug price caps, abortion pills, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a liver-drug approval, pharma’s positive outlook, and more - 6 months ago STAT+: Pharmalittle: We’re reading about Amazon delivering Zepbound, hemophilia treatments, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a failed schizophrenia drug trial, a Pfizer cancer drug, and more - 6 months ago STAT+: Pharmalittle: We’re reading about a nixed Medicare negotiation lawsuit, an Obamacare challenge, and more - 7 months ago STAT+: Pharmalittle: We’re reading about weight loss drugs, a cell therapy for melanoma, and more - 7 months ago STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages - 7 months ago STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more - 7 months ago STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more - 7 months ago STAT+: Pharmalittle: We’re reading about Novo buying Catalent, Amgen’s obesity drug, and more - 7 months ago STAT+: Pharmalittle: We’re reading about drug price hikes, Bayer strategic moves, and more - 8 months ago STAT+: Pharmalittle: We’re reading about a GSK deal, a probe into inhaler prices, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - 9 months ago STAT+: Pharmalittle: Bristol Myers to buy schizophrenia-drug maker; Servier found guilty of fraud - 9 months ago STAT+: Pharmalittle: Weight loss drugs are being paired with bariatric surgery; Carl Icahn plans to oust Illumina directors - 9 months ago STAT+: Pharmalittle: U.S. to impose inflation penalties on dozens of drugmakers; Supreme Court will decide abortion pill access - 9 months ago STAT+: Pharmalittle: Employers hire virtual providers as obesity drug gatekeepers; Vertex non-opioid nerve pain drug succeeds in mid-stage trial - 9 months ago STAT+: Pharmalittle: Sanofi scraps rare-disease drug deal under FTC pressure; patients regain weight after stopping Lilly’s Zepbound - 9 months ago STAT+: Pharmalittle: White House takes aim at pharma patents to lower drug prices; Sanofi CEO defends reducing earnings forecast - 9 months ago STAT+: Pharmalittle: Pfizer is leaving the BIO trade group; CVS drug-pricing plan may not lower costs for consumers - 10 months ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - 10 months ago STAT+: Pharmalittle: Novo Nordisk to spend $6 billion to boost production; FDA okays world’s first vaccine for chikungunya - 10 months ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - 10 months ago STAT+: Pharmalittle: FTC challenges ‘inaccurately or improperly’ listed patents; Elliott builds stake in BioMarin - 10 months ago STAT+: Pharmalittle: Vertex and U.K. at odds over value of CF meds; French authorities probe Sanofi over alleged market manipulation - 10 months ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - 11 months ago STAT+: Pharmalittle: Sanofi plans to spin off its consumer health biz; EMA says no evidence GLP-1 drugs linked to thyroid cancer - 11 months ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - 11 months ago STAT+: Pharmalittle: Roche buys Roivant bowel disease drug for $7.1 billion; AstraZeneca CEO calls report of imminent retirement ‘fake news’ - 11 months ago STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children - 11 months ago STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro - 11 months ago STAT+: Pharmalittle: Weight-loss drugs fuel boom for firms that fill syringes; employers that cover obesity drug may double in 2024 - 11 months ago STAT+: Pharmalittle: FDA panel lacks confidence in Amgen cancer drug data; weight loss drugs linked to rare stomach problems - 12 months ago STAT+: Pharmalittle: Novo faces patent challenge on Wegovy and Ozempic; Senate panel moves to address drug shortages - 12 months ago STAT+: Pharmalittle: More than 9 in 10 pharmacy techs report drug shortages; Yale and VA strike deal over ketamine patent royalties - 12 months ago STAT+: Pharmalittle: Lilly sues spas and compounders over ‘unapproved’ Mounjaro; nasal-spray EpiPen alternative suffers setback - 12 months ago STAT+: Lilly sues compounders, wellness centers and spas over unapproved versions of Mounjaro - 12 months ago STAT+: Pharmalittle: Cepheid agrees to sell a TB test at cost; Mallinckrodt weighs selling some or all businesses - 12 months ago STAT+: Pharmalittle: U.S. Chamber and feds clash on Medicare price negotiation; South Africa probes J&J over TB-drug pricing - 12 months ago
2	Adam Feuerstein STAT News Reporter at STATnews. Dog lover. Polk Award winner. Boston, Massachusetts biotech reporting	STAT+: Pharmalittle: We’re reading about a negative U.K. review of Leqembi, Bavarian Nordic’s strong earnings, and more - 25 days ago STAT+: First medicine developed to treat MASH expected to be approved soon - 6 months ago
3	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	eXmoor pharma’s manufacturing facility receives licence from MHRA - 27 days ago 2024 - 8 months ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings - 28 days ago Can BioNTech sustain a post-COVID mRNA pipeline? Oncology is the next hope. - about 1 month ago In a Duchenne market beset by problems, Capricor data marks a bright spot - about 1 month ago BMS’ long-standing leukemia blockbuster stares down its first generic - 2 months ago With historic MASH approval, Madrigal preps for launch and a public offering - 6 months ago
5	Meghana Keshavan STAT News Biotech nerd and writer @statnews. biotechwriting	Is pharma still fearful of the Inflation Reduction Act? - about 1 month ago A tough week for MDMA-assisted psychotherapy - about 1 month ago
6	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Eli Lilly to acquire Morphic for $3.2 billion - 2 months ago STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor - 5 months ago STAT+: Amgen goes all in on injectable obesity drug as it scraps early-stage pill - 5 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - 10 months ago
7	Ashley Gallagher, Associate Editor Pharmacy Times One of Cabra girls on GoggleboxIRL. Dublin City, Ireland televisionentertainment	Study: Mim8 Shows Reductions in Treated Bleeds for Patients With Hemophilia A - 3 months ago
8	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	Despite adcomm rejection, Lykos CEO sees future for MDMA drug - 3 months ago
9	https://www.facebook.com/ichiro51 GeekWire Tech news and analysis. Seattle, Washington technologystartupsnews	Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal - 6 months ago
10	Damian Garde STAT News Biotech reporter at STAT. Open to messages. biotechnologyjournalism	Wegovy and Zepbound get primetime treatment - 6 months ago STAT+: Pharmalittle: FDA rejects Merck cough medicine; Sanofi abandons an ADC for lung cancer - 9 months ago STAT+: Pharmalittle: Texas sues Pfizer over ADHD drugs; Merck buys a neuro startup - 10 months ago Eli Lilly gets FDA approval to sell Mounjaro as obesity drug called Zepbound - 10 months ago

Journalists covering M8 Pharmaceuticals